Mangesh A Thorat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1760151/publications.pdf

Version: 2024-02-01

101 papers	15,681 citations	186209 28 h-index	64755 79 g-index
105 all docs	105 docs citations	105 times ranked	14493 citing authors

#	Article	IF	Citations
1	The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. International Journal of Surgery, 2020, 84, 226-230.	1.1	5,005
2	The SCARE 2018 statement: Updating consensus Surgical CAse REport (SCARE) guidelines. International Journal of Surgery, 2018, 60, 132-136.	1.1	2,111
3	The SCARE Statement: Consensus-based surgical case report guidelines. International Journal of Surgery, 2016, 34, 180-186.	1.1	1,585
4	STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. International Journal of Surgery, 2019, 72, 156-165.	1.1	1,248
5	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. International Journal of Surgery, 2021, 96, 106165.	1.1	938
6	The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. International Journal of Surgery, 2017, 46, 198-202.	1.1	727
7	The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. International Journal of Surgery, 2018, 60, 279-282.	1.1	602
8	The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. International Journal of Surgery, 2020, 84, 231-235.	1.1	583
9	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	5.1	372
10	Preferred reporting of case series in surgery; the PROCESS guidelines. International Journal of Surgery, 2016, 36, 319-323.	1.1	351
11	Estimates of benefits and harms of prophylactic use of aspirin in the general population. Annals of Oncology, 2015, 26, 47-57.	0.6	303
12	FOXA1 Expression in Breast Cancerâ€"Correlation with Luminal Subtype A and Survival. Clinical Cancer Research, 2007, 13, 4415-4421.	3.2	220
13	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Research and Treatment, 2010, 123, 97-108.	1.1	165
14	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. International Journal of Surgery Open, 2021, 37, 100430.	0.2	117
15	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Journal of Clinical Pathology, 2007, 61, 327-332.	1.0	101
16	The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Research and Treatment, 2011, 126, 797-802.	1.1	99
17	Breast cancer prevention in high-risk women. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 18-31.	1.4	98
18	Role of Aspirin in Cancer Prevention. Current Oncology Reports, 2013, 15, 533-540.	1.8	88

#	Article	IF	Citations
19	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Annals of Medicine and Surgery, 2021, 72, 103026.	0.5	84
20	Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing. Disease Markers, 2011, 30, 151-161.	0.6	74
21	Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. European Journal of Epidemiology, 2015, 30, 5-18.	2.5	53
22	Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Disease Markers, 2011, 30, 151-61.	0.6	52
23	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Modern Pathology, 2010, 23, 270-275.	2.9	43
24	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. American Journal of Pathology, 2010, 176, 2139-2149.	1.9	40
25	Prostanoid receptor EP1 expression in breast cancer. Modern Pathology, 2008, 21, 15-21.	2.9	31
26	Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer and Prostatic Diseases, 2013, 16, 35-40.	2.0	31
27	Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast, 2015, 24, S51-S55.	0.9	31
28	Performance of the Xpert HPV assay in women attending for cervical screening. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 32-37.	4.5	29
29	Loss of ERÎ± and FOXA1 expression in a progression model of luminal type breast cancer: Insights from PyMT transgenic mouse model. Oncology Reports, 2010, 24, 1233-9.	1.2	24
30	Prognosis of Hormone-Dependent Breast Cancers: Implications of the Presence of Dysfunctional Transcriptional Networks Activated by Insulin via the Immune Transcription Factor T-bet. Cancer Research, 2010, 70, 685-696.	0.4	23
31	Role of Glucocorticoids in Breast Cancer. Current Pharmaceutical Design, 2010, 16, 3593-3600.	0.9	22
32	DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer, 2014, 14, 655.	1.1	22
33	Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience, 2015, 9, 595.	0.6	20
34	Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study. Clinical Breast Cancer, 2019, 19, e116-e126.	1.1	19
35	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. Breast Cancer Research, 2019, 21, 114.	2.2	17
36	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial. Clinical Cancer Research, 2021, 27, 5317-5324.	3.2	17

#	Article	IF	Citations
37	Delivering brief physical activity interventions in primary care: a systematic review. British Journal of General Practice, 2022, 72, e209-e216.	0.7	17
38	Revision surgery for breast cancer. Cancer, 2008, 113, 2347-2352.	2.0	16
39	Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Research and Treatment, 2010, 124, 327-335.	1.1	16
40	ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biology and Therapy, 2010, 10, 600-614.	1.5	15
41	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€“Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	1.4	15
42	Quantitative DNA methylation and recurrence of breast cancer: A study of 30 candidate genes. Cancer Biomarkers, 2012, 11, 75-88.	0.8	14
43	Preventing invasive breast cancer using endocrine therapy. Breast, 2017, 34, S47-S54.	0.9	14
44	Differential gene expression profiling of esophageal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 829-834.	0.4	12
45	Sentinel-Node Biopsy in Breast Cancer. New England Journal of Medicine, 2003, 349, 1968-1971.	13.9	11
46	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	1.4	11
47	Amplified in breast cancer 1 expression in breast cancer. Histopathology, 2008, 53, 634-641.	1.6	10
48	Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK. International Journal of Surgery Case Reports, 2015, 16, 77-80.	0.2	10
49	Uptake Characteristics of FDG in Multiple Juvenile Cellular Fibroadenomata of the Breast. Clinical Nuclear Medicine, 2007, 32, 203-204.	0.7	9
50	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial. Clinical Cancer Research, 2021, 27, 2861-2867.	3.2	9
51	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 505-505.	0.8	7
52	What caused the decline in US breast cancer incidence?. Nature Clinical Practice Oncology, 2008, 5, 314-315.	4.3	6
53	FOXP3 expression and nodal metastasis of breast cancer. Cellular Oncology (Dordrecht), 2013, 36, 405-409.	2.1	6
54	Optimum cancer careâ€”an unaffordable goal?. Lancet Oncology, The, 2004, 5, 529-530.	5.1	5

#	Article	IF	Citations
55	Radiation Therapy for Ductal Carcinoma In Situ: Is It Really Worth It?. Journal of Clinical Oncology, 2007, 25, 461-462.	0.8	5
56	Five Genetic Variants Associated with Prostate Cancer. New England Journal of Medicine, 2008, 358, 2738-2741.	13.9	5
57	COX-2 Expression Does Not Correlate with Microvessel Density in Breast Cancer. Pathobiology, 2009, 76, 39-44.	1.9	5
58	Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts). Journal of Clinical Oncology, 2008, 26, 1019-1019.	0.8	5
59	Sentinel lymph node assessment in breast cancer patients receiving neoâ€adjuvant chemotherapy: to biopsy before or after?. International Journal of Cancer, 2016, 138, 267-270.	2.3	4
60	Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. Nature Clinical Practice Oncology, 2006, 3, E1-E1.	4.3	4
61	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. The Cochrane Library, 2021, 2021, CD013091.	1.5	4
62	Autoantibodies in Prostate Cancer. New England Journal of Medicine, 2005, 353, 2815-2817.	13.9	3
63	Are there distinct lymphatic flow patterns in the Breast?. Medical Hypotheses, 2006, 66, 1040-1041.	0.8	3
64	Gene-signature-based prognostic tools in breast cancer: not yet. Lancet, The, 2007, 369, 1428.	6.3	3
65	Should we undertake an MRI breast screening trial?. Lancet, The, 2007, 370, 1902.	6.3	2
66	Individualised benefitâ€“harm balance of aspirin as primary prevention measure â€“ a good proof-of-concept, but could have been betterâ€¦. BMC Medicine, 2016, 14, 101.	2.3	2
67	Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinomain situ: Results from the UK/ANZ DCIS trial. , 2016, , .		2
68	VEGFA amplification/deletion in human breast tumors.. Journal of Clinical Oncology, 2010, 28, e21017-e21017.	0.8	2
69	RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer.. Journal of Clinical Oncology, 2011, 29, 634-634.	0.8	2
70	Optimum cancer careâ€”an unaffordable goal?. Lancet Oncology, The, 2004, 5, 530.	5.1	1
71	Trastuzumab for early breast cancer. Lancet, The, 2006, 367, 108.	6.3	1
72	Medical research in India. Lancet, The, 2006, 368, 643-644.	6.3	1

#	Article	IF	Citations
73	PSA testing for prostate cancer screening â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e3.	5.1	1
74	Reply to the letter to the editor â€˜The harms of low-dose aspirin prophylaxis are overstatedâ€™ by P. Elwood and G. Morgan. Annals of Oncology, 2015, 26, 442-443.	0.6	1
75	Assessing opportunities for coordinated <scp>R</scp>&<scp>D</scp> in early cancer detection and management in <scp>E</scp>urope. International Journal of Cancer, 2017, 140, 1700-1701.	2.3	1
76	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. The Cochrane Library, 2018, , .	1.5	1
77	Liquid biopsy for cancer diagnosis and screening â€“ The promise and challenges. Annals of Clinical Biochemistry, 2019, 56, 420-423.	0.8	1
78	WITHDRAWALâ€”Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. Tumori, 2020, 106, NP2-NP4.	0.6	1
79	Radical and Simple Mastectomy. New England Journal of Medicine, 2002, 347, 2170-2171.	13.9	0
80	Does primary tumor location have prognostic significance in operable breast cancer?. Nature Clinical Practice Oncology, 2005, 2, 396-397.	4.3	0
81	Developing Countries: An Evolving Opportunity for Oncologic Research. World Journal of Surgery, 2006, 30, 1173-1176.	0.8	0
82	Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors?. Current Diagnostic Pathology, 2007, 13, 116-125.	0.4	0
83	MRI breast screening. Lancet, The, 2008, 371, 1415.	6.3	0
84	Obesity downregulates innate and adaptive immunity genes in the pancreatic cancer microenvironment. Journal of the American College of Surgeons, 2009, 209, S118-S119.	0.2	0
85	5BA Identification of gene expression profiles that predict response to HER2-targeted therapy. European Journal of Cancer, Supplement, 2009, 7, 5.	2.2	0
86	Comment on "Dynamic response to heat - a novel physical characteristic of breast cancer". International Journal of Surgery, 2009, 7, 173.	1.1	0
87	Tackling breast cancer in India. Lancet, The, 2012, 379, 2340-2341.	6.3	0
88	A major flaw in â€œAwareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based surveyâ€• Maturitas, 2016, 88, 45.	1.0	0
89	Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. Nature Clinical Practice Oncology, 2006, 3, E1-E1.	4.3	0
90	Regulatory T cells (T-Regs) in breast cancer sentinel nodes (SN): FOXP3 expression analysis. Journal of Clinical Oncology, 2008, 26, 22175-22175.	0.8	0

#	Article	IF	Citations
91	Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC).. , 2009, , .		0
92	Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy.. Journal of Clinical Oncology, 2010, 28, 1036-1036.	0.8	0
93	The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort.. Journal of Clinical Oncology, 2010, 28, 669-669.	0.8	0
94	Analysis of temporal trends in the BMJ archive. BMJ: British Medical Journal, 2010, 341, c3306-c3306.	2.4	0
95	Abstract PD04-08: Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of â€˜intermediate gradeâ€™ disease and gives clinically meanignful information.. , 2012, , .		0
96	Abstract P3-07-01: Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinomain situ: Results from the UK/ANZ DCIS trial. , 2016, , .		0
97	Abstract 1788: Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. , 2016, , .		0
98	Abstract P1-09-06: Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinomain situ: Results from the UK/ANZ DCIS trial. , 2017, , .		0
99	Abstract P5-06-15: Computer extracted features of nuclear shape, orientation disorder and texture from H&E Whole slide images are associated with disease-free survival in ductal carcinoma in situ (DCIS). , 2020, , .		0
100	Herceptin in early breast cancer: a call for judicious use. The National Medical Journal of India, 2005, 18, 315-7.	0.1	0
101	Cancer immunotherapeutics: raising the ante. The National Medical Journal of India, 2006, 19, 140-50.	0.1	0